Coverage / CLRB / Trade Card

CLRB

Cellectar Biosciences Inc

OPPORTUNISTIC BUY Analysis generated 2026-10-28 Market data as of 2026-11-12 Market data 3 days old USD 1.16 Healthcare - BiotechnologyAWAIT ENTRY
BLOCKED - NOT ACTIONABLEMethodology gate: buy_preconditions_failed
64

Position levels

Currenttoday
USD 1.16
Buy <=wait / entry
USD 1.07
Trim >=take some off
USD 1.80
Thesis breakThe thesis would be invalidated by a failed or materially inconclusive confirmat...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case37%100 / 10037.0
Base case50%62 / 10031.0
Bear case13%10 / 1001.3
Weighted conviction64 / 100 - OPPORTUNISTIC BUY

Top risks

  • Oversubscribed financing up to $140 million
  • 79.2% major response rate in Phase 2 CLOVER-WaM subgroup for iopofosine I 131
  • Complete response lasting more than eight years in heavily pretreated DLBCL patient
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.

\n